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 In the July 25, 2011 Federal Register, the Department of Health and Human Services (HHS) released an Advanced Notice of Proposed Rule Making (ANPRM) changes in the “Common 
Rule,” entitled, “Human Subjects Research Protections: enhancing 
protections for research subjects and reducing burden, delay, and 
ambiguity for investigators.” Th e enhancements were proposed to 
“…ensure the highest standards of protections for human subjects 
involved in research, while enhancing eff ectiveness of oversight.” 
Despite the seeming opacity of the announcement to many, and 
its arcane target, the procedures for protecting human research 
subjects, this represents a major event for clinical and translational 
researchers. Th e Society for Clinical and Translational Science, 
accordingly, will have weighed in on these changes before the 
deadline for comment, October 26, 2011. Once the rules have been 
revised, there will be another chance for comment, and all members 
of the translational science community should take the opportunity 
to weigh in on the changes if they have not already done so. 
 We all endorse vigorous protections of research participants. 
Aft er a history of lack of reliable protections over the past several 
decades, research regulations and practices have improved 
signifi cantly. In 1974, HHS human subject protection regulations 
were fi rst issued based on statutory authority under the Code 
of Federal Regulations (CFR) as 45 CFR, part 46. In 1978, the 
National Commission for the Protection of Human Subjects 
of Biomedical and Behavioral Research published “Ethical 
Principles and Guidelines for the Protection of Human Subjects 
of Research,” known as the Belmont Report. It identifi ed the three 
fundamental ethical principles that are oft en cited as the basis 
for human subject research: respect for persons, benefi cence, and 
justice. Th e current HHS regulations include fi ve subparts, of 
which Subpart A (which specifi es the basic set of protections for 
all human subjects of research conducted or supported by HHS) 
and Subpart E, (which requires registration of institutional review 
boards [IRBs] for human research studies) are most relevant to 
clinical research. In 1991, 15 federal departments and agencies 
together issued the “Federal Policy for the Protection of Human 
Research Subjects,” known as the “Common Rule” based on the 
HHS 45 CFR part 46 Subpart A, providing identical language in 
the regulations of those departments and agencies, and technical 
amendments were made in 2005. 
 The changes now proposed by HHS are designed to 
strengthen protections for human research subjects. (Th e full 
ANPRM can be seen at  http://www.hhs.gov/ohrp , and additional 
information can be found at  http://www.hhs.gov/ohrp/
humansubjects/anprm2011page.html . Particularly helpful is a 
table of comparison between the current rules and the changes 
being considered at  http://www.hhs.gov/ohrp/humansubjects/
anprmchangetable.html .) Some of the issues on which comments 
were invited included:
 (1)  Revising the existing risk-based framework to more accurately 
calibrate the level of review to the level of risk. 
(2)  Using a single IRB review for all domestic sites of multisite 
studies. 
(3)  Updating the forms and processes used for informed 
consent. 
(4)  Establishing mandatory data security and information 
protection standards for all studies involving identifi able or 
potentially identifi able data. 
(5)  Implementing a systematic approach to the collection and 
analysis of data on unanticipated problems and adverse 
events across all trials to harmonize the complicated array 
of defi nitions and reporting requirements, and to make the 
collection of data more effi  cient. 
(6)  Extending federal regulatory protections to apply to all 
research conducted at US institutions receiving funding from 
the Common Rule agencies. 
(7)  Providing uniform guidance on federal regulations. 
 
 Th ere are several changes proposed in the ANPRM that are 
particularly attractive for streamlining clinical research. One of 
the most important is the clear stratifi cation of research based on 
risk into three levels, and the implications for diff erent types of 
research. Th e lowest risk level is research that is only for collection 
of information, which would be “excused” from IRB review. 
Th e next level is research in which there is an intervention that 
adds to that intrinsic to usual care, but the intervention itself is 
only of minimal risk, which is defi ned as not having higher risk 
than “…encountered in daily life or during the performance of 
routine physical or psychological examinations or tests.” Th is 
could include additional testing due to the study, such as the 
performance of blood tests. Such research would receive a brief 
expedited review, by one person. Alternatively, the highest level 
of risk in research is designated if there are interventions and/or 
tests of more than minimal risk; for such studies, standard IRB 
review would be done. 
 Another important change is the proposal of standard 
simple one-time research consent for patients to sign upon 
initiating care at an institution or practice. From then on, all 
the patient’s information (and biological specimens) can be 
used for research purposes—as long as reviews are done as 
mandated (as above) and rigorous standards of information 
protection are maintained. Th e standardization of this, and its 
intended wide promulgation, should greatly enhance clinical 
and translational research. 
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 It is worth noting that the combination of the proposed 
changes related to the three levels of research risk, especially the 
lowest risk category, with the use of the one-time consent for 
use of patient information, could have a major impact on the 
performance of clinical research. For example, were researchers 
to compare by random assignment, two alternative treatments 
that are part of usual accepted care and then collect medical 
information to compare the outcomes, this project would be 
“excused” from IRB review and would have no further need for 
consent other than the initial global permission. Th e reason this 
would not be considered to represent minimal risk is that there 
is no incremental risk added by the study—the only risk is that 
related to usual care. Th is clearly should facilitate clinical research, 
and especially comparative eff ectiveness research. 
 Another important change proposed is that, if multiple US 
institutions are used, a single IRB at one institution, presumably 
that of the principal investigator, would be able to approve the 
study for the entire consortium. Th is would lessen duplicative 
work and delays and should eliminate the confusion that can 
arise from diff erent IRBs having diff erent judgments on the same 
study—something commonly encountered at the present time. 
Th ere have been many attempts to fi nd ways to accomplish this, 
by use of federated IRBs and other approaches, all of which have 
taken years to develop; this change could resolve all this and 
greatly expedite multicenter investigation. 
 Additional changes that should lessen the burden on 
investigators and many needless reviews by institutional 
IRBs include the elimination of the need to have annual IRB 
reviews aft er the study intervention is completed and only 
follow-up data collection and/or analysis is being done as well 
as clarifi cation of the exemption categories. Th e ANPRM has 
specifi cally asked for public commentary to identify areas of 
research that do not warrant the current degree of regulatory 
oversight so that review requirements are better calibrated to 
the level of risk. 
 In sum, we believe that the proposed changes in the Common 
Rule will have a very salutary impact on our ability to conduct 
translational research. Indeed, not only should they improve the 
effi  ciency of clinical research without diminishing important 
human subject protections by removing many delays from the 
research process, results will be available sooner, and the impact 
on health greater. Th e SCTS, representing member interests, has 
sent comments representing these views to HHS. Th ese changes 
in the Common Rule will be a common good. CTS
